- Overview of how companies are accommodating increasingly customized clinical trial design and execution
- Discussion of approaches most resonating with panel member companies
- Review of implementation challenges and how they have been overcome
- Discussion of downstream opportunities being pursued
- Implementing ICH E6(R3) expectations
- Defining effective oversight and KPIs
- Strengthening sponsor – lab partnerships
- Managing compliance and quality risks
- Lessons learned and future priorities
- Review off recent data quantifying the magnitude of the problem
- Presentation of empirical evidence capturing underlying factors contributing to the problem
- Discussion of opportunities to optimise protocol design and improve clinical trial performance
